A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-02-23
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-23 (study day 317); relationship: not assessed
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-01 (study day 415); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-24 (study day 469); relationship: not assessed
Data queries
No data queries.